FLT-PET / MRI Brain Mets
Launched by UNIVERSITY HEALTH NETWORK, TORONTO · Jan 24, 2020
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to differentiate between two complications that can occur after treatment for brain metastases, which are cancer tumors that have spread to the brain. After a treatment called stereotactic radiosurgery (SRS), some patients may experience radionecrosis (RN), where healthy brain tissue is damaged, or tumor progression, where the cancer continues to grow. Both conditions can cause similar symptoms and look alike on standard imaging tests, making it hard for doctors to know which one is affecting a patient. This trial aims to see if a special imaging technique called hybrid FLT-PET/MRI can help doctors tell the difference without needing surgery.
To be eligible for this study, participants must be at least 18 years old, have been treated with SRS for brain metastases before, and have new brain lesions that may be RN or tumor progression. They should also be scheduled for surgery on the affected area. Participants will undergo the hybrid imaging procedure before their surgery, which will help provide important information for their diagnosis and treatment plan. It's worth noting that this trial is currently recruiting patients, and individuals who meet the criteria can contribute to advancing our understanding of these conditions.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. 18 years or older
- • 2. Previously treated with SRS for BrM
- • 3. New intracranial lesion with clinical and radiographic findings suspicious for either RN or tumour progression
- • 4. May be planned surgical resection of the lesion in question. The determination that the lesion is appropriate for and may require surgical resection will be made by the multi-disciplinary brain metastasis team. Surgery is preferred but not required. If a patient is planned for surgery, the date does not need to be established and the patient does not need to have consented in order to be eligible for this study, however the imaging procedure will need to occur prior to the date of surgery.
- • 5. A negative serum pregnancy test within the two-week interval immediately prior to PET-MRI imaging for women of child-bearing age
- • 6. Ability to provide written informed concern to participate in the study
- Exclusion Criteria:
- • 1. Previous radiotherapy to the intended treatment volume
- • 2. Active malignancy other than sarcoma
- • 3. Inability to remain supine for at least 60 minutes
- • 4. Pregnancy or breast feeding
- • 5. Age \<18 years
- • 6. Failure to provide written informed consent
- • 7. Contraindication for MRI as per current institutional guidelines
About University Health Network, Toronto
University Health Network (UHN), based in Toronto, is a leading academic health sciences center dedicated to advancing patient care through innovative research and education. As a prominent sponsor of clinical trials, UHN integrates cutting-edge scientific discoveries with clinical practice, facilitating the development of new therapies and treatment modalities. With a commitment to improving health outcomes, UHN collaborates with a diverse network of researchers, healthcare professionals, and industry partners, fostering an environment that prioritizes patient safety and ethical standards in clinical research. Through its extensive resources and expertise, UHN plays a pivotal role in transforming healthcare and enhancing the quality of life for patients both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toronto, Ontario, Canada
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials